Literature DB >> 12433771

Education and debate: Making regulation responsive to commercial interests: streamlining drug industry watchdogs.

John Abraham1, Danielle Bardelay, Christophe Kopp, J D Kleinke, Emma Bennion.   

Abstract

Keywords:  Health Care and Public Health; Legal Approach

Mesh：

Year:  2002        PMID： 12433771      PMCID： PMC1124641          DOI： 10.1136/bmj.325.7373.1164

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Patient care (empowerment): the view from a national society.

Authors:  M Baker
Journal:  BMJ       Date:  2000-06-17

2.  Adjusting Europe's drug regulation to public health needs.

Authors:  S Garattini; V Bertele
Journal:  Lancet       Date:  2001-07-07       Impact factor: 79.321

3.  Linking health technology assessment to practice. Interview by Abi Berger.

Authors:  R Rosen; J Gabbay
Journal:  BMJ       Date:  1999-11-13

4.  Efficacy, safety, and cost of new anticancer drugs.

Authors:  Silvio Garattini; Vittorio Bertele
Journal:  BMJ       Date:  2002-08-03

Review 5.  The drug lag issue: the debate seen from an international perspective.

Authors:  F Andersson
Journal:  Int J Health Serv       Date:  1992       Impact factor: 1.663

6.  Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan.

Authors:  D A Kessler; A E Hass; K L Feiden; M Lumpkin; R Temple
Journal:  JAMA       Date:  1996-12-11       Impact factor: 56.272

Review 7.  Whose illness is it anyway? Why patient perceptions matter.

Authors:  A F Cooper
Journal:  Int J Clin Pract       Date:  1998 Nov-Dec       Impact factor: 2.503

8.  Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.

Authors:  M C Kurth; C H Adler; M S Hilaire; C Singer; C Waters; P LeWitt; D A Chernik; E E Dorflinger; K Yoo
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910
  8 in total
  3 in total

1.  Regulation and the social licence for medical research.

Authors:  Mary Dixon-Woods; Richard E Ashcroft
Journal:  Med Health Care Philos       Date:  2008-07-17

Review 2.  Ocular medicines in children: the regulatory situation related to clinical research.

Authors:  Filomena Fortinguerra; Antonio Clavenna; Maurizio Bonati
Journal:  BMC Pediatr       Date:  2012-01-20       Impact factor: 2.125

3.  Policy Analysis Of Iranian Pharmaceutical Sector; A Qualitative Study.

Authors:  Farbod Ebadi Fardazar; Ali Sarabi Asiabar; Hossein Safari; Mojgan Asgari; Ali Saber; Amir Ali Ebadi Fard Azar
Journal:  Risk Manag Healthc Policy       Date:  2019-11-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.